Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

TCON

Phase 2

TRC102

Mesothelioma & Granulosa cell ovarian cancer

2025

Sponsored by NCI. 2/22- Trial initiated. 6/2022- Enrollment started and target completion w/ data in 2025. Presented poster at ASCO 2023.

Data Readout

ANAB

Phase 2

Rosnilimab (ANB030) (PD-1 agonist)

Moderate-to-severe Ulcerative colitis (UC)

Q4 2025

11/02/23- Initiate trial in Q4 2023. 2/12/25- Top-line Week 12 Ph2 data in Q4 2025.

Data readout

ZBIO

Phase 3

Obexelimab (CD19xFcyRIIb)

Immunoglobulin G4-Related Disease (IgG4-RD)

YE 2025

INDIGO trial. 11/12/24- Completed enrollment w/ topline data by YE 2025.

Data readout

ARCT

Phase 1

ARCT-2304

H5N1 avian influenza

H2 2025

11/11/24- Received IND clearance. 12/24- Dosed first patient. 3/6/25- Interim data in H2 2025.

Data readout

COGT

Phase 3

Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib

GIST (Gastrointestinal Stromal Tumors)

YE 2025

PEAK trial. 8/8/23- Presented lead-in data from ongoing combo therapy at ASCO '23. Updated data at CTOS '23 on 11/04/23. 9/3/24- Completed enrollment w/ top-line results by the end of 2025.

Data readout

WVE

Phase 2

WVE-007 [GalNAc-small interfering RNA (siRNA)] INHBE Program

Obesity

H2 2025

INLIGHT Trial. 5/9/24- Initiate trial in Q1 2025. 12/23/24- CTA submitted to FDA. 2/6/25- Ph2 INLIGHT trial initiated. 3/4/25- Clinical data in H2 2025.

Data readout

BMEA

Phase 2

BMF-219 (icovamenib)

Type 1 diabetes

2025

Big Mover: COVALENT-112 study. 1/8/24- First patient dosed. 1/4/24- Initial data from first 2 patients. 9/26/24- Lifted clinical hold. 10/29/24- Ph2b 26wk data readout in Dec 2024. 12/17/24- Planning to continue enrollment, so company can provide complete update in 2025.

Data readout

IMMP

Phase 1

Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab

NSCLC

2025

INSIGHT-003 & -004. Final -004 data at ASCO2021. 11/14/24- Presented survival data. 1/6/25- Enrollment completed. Data updates from INSIGHT-003 are expected in 2025 and beyond.

Data readout

INKT

Phase 2

AgenT-797 + botensilimab/balstilimab

Second line gastroesophageal cancer

H2 2025

2/14/24- First patient dosed. 11/7/24- Presentation at SITC 2024. 1/24/25- Clinical update in H2 2025. 2/13/25- Present updated Ph2 data at AACR IO on February 25, 2025.

Data readout

EVAX

Phase 2

EVX-01 + pembrolizumab

Metastatic Melanoma

H2 2025

4/17/24- Frist patient dosing completion. 6/3/24- New Data at ASCO '24. 9/9/24- 1-year clinical efficacy data readout. Present at ESMO '24 on 9/14. 12/9/24- Complete patient dosing and biomarker/immunogenicity data in H1 2025. Clinical data readout in H2 2025. 1/15/25- Completed dosing in Ph2 trial.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20